<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00519818</url>
  </required_header>
  <id_info>
    <org_study_id>070211</org_study_id>
    <nct_id>NCT00519818</nct_id>
  </id_info>
  <brief_title>Comparison of Two Forms of Hydrocortisone in Patients With Congenital Adrenal Hyperplasia</brief_title>
  <official_title>A Phase 2, Open Label, Crossover Pharmacokinetic and Pharmacodynamic Study to Compare Chronocort Versus Cortef in Patients With CAH</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diurnal Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health Clinical Center (CC)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Diurnal Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will test a new, extended release form of hydrocortisone called Chronocort in
      patients with congenital adrenal hyperplasia (CAH). People with CAH do not make enough of the
      adrenal hormones cortisol and aldosterone, and their adrenal glands make too much of the sex
      hormone androgen. Medicines called glucocorticoids (hydrocortisone, dexamethasone and
      prednisone) are currently used to treat CAH, but finding the best dose of these drugs that
      effectively lowers androgens without causing undesirable side effects, such as weight gain
      and slow growth rate in children, is often difficult to achieve.

      Adolescents and adults with CAH due to 21-hydroxylase deficiency may be eligible for this
      study. Children 16 years of age and older are eligible with confirmation by bone age that
      they are no longer growing.

      Participants undergo the following tests and procedures during two inpatient visits one month
      apart at the NIH Clinical Center:

        -  Medical history and physical examination.

        -  Medications: Following 7 days of Cortef (standard drug treatment for CAH), patients
           begin taking Chronocort on day 3 of hospitalization and continue the tablets once a day
           for 1 month.

        -  Blood tests: A catheter (plastic tube) is inserted in a vein and left in place for
           frequent blood draws in order to avoid repeated needlesticks. Blood is drawn for
           chemistries, blood count, pregnancy test in women, and for serial tests (up to 26
           samples in a 24-hour period) to measure hormone levels.

        -  24-hour urine test.

        -  Height and weight measurements.

      Between the two hospitalizations, patients are contacted by NIH weekly to check for possible
      side effects from Chronocort. Two weeks after the first visit, patients also will have blood
      drawn by their regular doctor or a local clinic. A few days before the second
      hospitalization, patients undergo a 20-minute telephone questionnaire about energy level and
      well being.

      About 30 days after discharge from the second hospitalization, patients are followed up with
      a telephone call to see how they are doing.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency is a disease of the
      adrenal cortex characterized by cortisol deficiency with or without aldosterone deficiency,
      and androgen excess. The severe or classic form occurs in 1 in 15,000 births worldwide, while
      the mild non-classic form is a common cause of hyperandrogenism. The discovery of
      glucocorticoid therapy as a treatment for CAH occurred in the 1950's resulting in patients
      with classic CAH surviving to live a normal lifespan. However, existing treatment is
      suboptimal and many unresolved clinical problems exist. Standard hormone replacement often
      fails to normalize the growth and development of children with CAH, and adults may experience
      iatrogenic Cushing syndrome, hyperandrogenism, infertility or the development of the
      metabolic syndrome. Chronocort, a newly-developed formulation of hydrocortisone, results in a
      slow release of hydrocortisone that is designed to mimic the normal cortisol circadian
      rhythm. This new medical strategy, physiologic cortisol replacement, offers the prospect of
      an improved outcome of treatment. Chronocort has been safely given to healthy adult males in
      pharmacokinetic studies. This first ever study in patients with CAH is a
      pharmacokinetic/pharmacodynamic study comparing Chronocort to Cortef, the conventional
      immediate-release form of hydrocortisone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2007</start_date>
  <completion_date type="Actual">May 2009</completion_date>
  <primary_completion_date type="Actual">May 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Chronocort vs. Cortef Cortisol Concentrations (AUC Over 24 Hours - Time Points 0,.5,1,1.5,2,3,4,5,6,7,8,10,10.5,11, 11.5,12,13,15,17,17.5,18,18.5,19,20,22,24 Post Dose).</measure>
    <time_frame>Cortef after one week, Chronocort after one month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>17 Hydroxyprogesterone at 08.00 Hours</measure>
    <time_frame>Cortef after one week compared with Chronocort after one month</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Congenital Adrenal Hyperplasia</condition>
  <condition>21-Hydroxylase Deficiency</condition>
  <condition>Adrenogenital Syndrome</condition>
  <arm_group>
    <arm_group_label>Cortef and Chronocort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cortef 3 times daily(total dose 30 mg)for minimum of 7 days followed by Chronocort 30 mg once daily nigh time dose for 28 +/- 3 days duration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Chronocort</intervention_name>
    <description>Chronocort 30 mg once daily nigh time dose for 28 +/- 3 days duration</description>
    <arm_group_label>Cortef and Chronocort</arm_group_label>
    <other_name>Hydrocortisone modified release tablet treatment</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cortef</intervention_name>
    <description>Cortef 3 times daily(total dose 30 mg)for minimum of 7 days</description>
    <arm_group_label>Cortef and Chronocort</arm_group_label>
    <other_name>Hydrocortisone immediate release tablet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        -  INCLUSION CRITERIA:

        Satisfactory pre-trial screening

        Provision of signed written informed consent and written assent from patients less than 18
        years old, as applicable.

        Good general health.

        Females of childbearing potential must have a negative pregnancy test initially and at all
        visits. Females who are engaging in sexual intercourse must be using medically acceptable
        method of contraception.

        EXCLUSION CRITERIA:

        Co-morbid condition requiring daily administration of a medication that induces hepatic
        enzymes or interferes with the metabolism of glucocorticoids.

        Clinical or biochemical evidence of hepatic or renal disease. Creatinine above the normal
        range or elevated liver function tests (Transaminases greater than 1.5 the upper limits of
        normal).

        Females who are pregnant or lactating.

        Patients with any other significant medical or psychiatric conditions that in the opinion
        of the Investigator would preclude participation in the trial.

        Participation in another clinical trial of an investigational or licensed drug or device
        within 3 months prior to inclusion in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Deborah Merck, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Institutes of Health (NIH)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Institutes of Health Clinical Center, 9000 Rockville Pike</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Therrell BL. Newborn screening for congenital adrenal hyperplasia. Endocrinol Metab Clin North Am. 2001 Mar;30(1):15-30. Review.</citation>
    <PMID>11344933</PMID>
  </reference>
  <reference>
    <citation>Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet. 2005 Jun 18-24;365(9477):2125-36. Review.</citation>
    <PMID>15964450</PMID>
  </reference>
  <reference>
    <citation>Krieger DT, Allen W, Rizzo F, Krieger HP. Characterization of the normal temporal pattern of plasma corticosteroid levels. J Clin Endocrinol Metab. 1971 Feb;32(2):266-84.</citation>
    <PMID>4321505</PMID>
  </reference>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 22, 2007</study_first_submitted>
  <study_first_submitted_qc>August 22, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 23, 2007</study_first_posted>
  <results_first_submitted>June 28, 2011</results_first_submitted>
  <results_first_submitted_qc>August 12, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 27, 2014</results_first_posted>
  <last_update_submitted>February 26, 2016</last_update_submitted>
  <last_update_submitted_qc>February 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Congenital Adrenal Hyperplasia</keyword>
  <keyword>Hydrocortisone</keyword>
  <keyword>Pharmacokinetic</keyword>
  <keyword>Pharmacodynamic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperplasia</mesh_term>
    <mesh_term>Adrenal Hyperplasia, Congenital</mesh_term>
    <mesh_term>Adrenogenital Syndrome</mesh_term>
    <mesh_term>Adrenocortical Hyperfunction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrocortisone 17-butyrate 21-propionate</mesh_term>
    <mesh_term>Hydrocortisone acetate</mesh_term>
    <mesh_term>Cortisol succinate</mesh_term>
    <mesh_term>Hydrocortisone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Cortef Then Chronocort</title>
          <description>Hydrocortisone immediate release tablet treatment then Modified release hydrocortisone</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cortef Then Chronocort</title>
          <description>Hydrocortisone immediate release 3 times daily total dose 30mg for 7 days, then hydrocortisone modified release tablet 30mg once nightly for 28days</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="14"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.8" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Chronocort vs. Cortef Cortisol Concentrations (AUC Over 24 Hours - Time Points 0,.5,1,1.5,2,3,4,5,6,7,8,10,10.5,11, 11.5,12,13,15,17,17.5,18,18.5,19,20,22,24 Post Dose).</title>
        <time_frame>Cortef after one week, Chronocort after one month</time_frame>
        <population>Per protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Cortef</title>
            <description>Hydrocortisone immediate release tablet</description>
          </group>
          <group group_id="O2">
            <title>Chronocort</title>
            <description>Hydrocortisone modified release tablet treatment</description>
          </group>
        </group_list>
        <measure>
          <title>Chronocort vs. Cortef Cortisol Concentrations (AUC Over 24 Hours - Time Points 0,.5,1,1.5,2,3,4,5,6,7,8,10,10.5,11, 11.5,12,13,15,17,17.5,18,18.5,19,20,22,24 Post Dose).</title>
          <population>Per protocol</population>
          <units>h*nmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5380" spread="414"/>
                    <measurement group_id="O2" value="3973" spread="166"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>17 Hydroxyprogesterone at 08.00 Hours</title>
        <time_frame>Cortef after one week compared with Chronocort after one month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cortef</title>
            <description>Hydrocortisone immediate release tablet</description>
          </group>
          <group group_id="O2">
            <title>Chronocort</title>
            <description>Hydrocortisone modified release tablet treatment</description>
          </group>
        </group_list>
        <measure>
          <title>17 Hydroxyprogesterone at 08.00 Hours</title>
          <units>nmol/l</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.4" spread="27.9"/>
                    <measurement group_id="O2" value="86.9" spread="181.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events for each subject were followed for 1 week in Cortef, 4 weeks on Chronocort and 4 weeks follow-up.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Chronocort</title>
          <description>Hydrocortisone modified release tablet</description>
        </group>
        <group group_id="E2">
          <title>Cortef</title>
          <description>Hydrocortisone immediate release tablet</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="14"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Richard JM Ross</name_or_title>
      <organization>Diurnal Ltd</organization>
      <phone>0044 114 2712386</phone>
      <email>r.j.ross@sheffield.ac.uk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

